Cell line · CVCL_1056
Papers119
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 119
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Tumor-Induced PDPN+ Lymphatic-like Endothelial Cells Promote Clear-Cell Renal Cell Carcinoma Progression Through Reciprocal BMP10-CXCL13 Signaling. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Optimization of hinge domain enhances antitumor efficacy of globo H-targeted CAR-T cells in solid tumor models. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IDMME and IDMDE: inducible CRISPR-dCasRx platforms for spatiotemporal RNA m5C editing. | Genome Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and Identifies UCN-Mediated Immune Evasion as a Therapeutic Vulnerability: Evidence from In Vitro and In Vivo Studies. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 2,3-Bisphosphoglycerate Mutase (BPGM), a Metabolic Player Shaping Stress-Adaptive Transcriptional States in Clear Cell Renal Cell Carcinoma. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERMP1 Exerts Tumor-Suppressive Functions in KIRC by Inhibiting PI3K/AKT Signaling and Remodeling the Immune Microenvironment: A Pan-Cancer Analysis. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD70 regulates the NF1/Ras/ERK axis to promote metastatic potential in clear cell renal cell carcinoma. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma. | BMC Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. | Commun Med (Lond) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1056/papers